Publications by authors named "Qiuxiang Zheng"
In our prior research, it was noted that slit guidance ligand 3 (SLIT3), a member of the SLIT-secreted protein family, may play a potential role in tumorigenesis. In addition, our prior work has found that the SLIT3 gene is highly methylated, especially in advanced-stage lung cancer tissues. Herein, we propose the hypothesis that abnormal SLIT3 expression may be linked to lung cancer development.
View Article and Find Full Text PDFBackground: Hepatocellular carcinoma (HCC) is widely recognized as a globally prevalent malignancy. Immunotherapy is a promising therapy for HCC patients. Increasing evidence suggests that lncRNAs are involved in HCC progression and immunotherapy.
View Article and Find Full Text PDFArticle Synopsis
- Researchers are studying a type of liver cancer called hepatocellular carcinoma (HCC) which makes it hard for people to survive because it spreads aggressively.
- They used special computer tools to analyze information from different cell types in HCC and found 9 different groups of cells.
- Four specific cell groups were linked to the cancer spreading more, especially one called NDUFA4L2 that seems to help the cancer grow and spread faster.
Background: Only a limited number of studies considered the combined chemo-radiation therapy after surgery for treating locally advanced rectal cancer. Comparative studies on laparoscopic and open procedures indicated that laparoscopy surgery may be associated with fewer postoperative complications. Despite encouraging results from rectal cancer patients who received neoadjuvant chemo-radiotherapy prior to laparoscopic surgery, the acceptance of this procedure remains controversial, and conflicting evidence exists only in the form of retrospective trials.
View Article and Find Full Text PDFUsing Naïve Bayes Algorithm to Estimate the Response to Drug in Lung Cancer Patients.
Comb Chem High Throughput Screen
July 2019
Aim And Objective: Lung cancer is a highly heterogeneous cancer, due to the significant differences in molecular levels, resulting in different clinical manifestations of lung cancer patients there is a big difference. Including disease characterization, drug response, the risk of recurrence, survival, etc.
Method: Clinical patients with lung cancer do not have yet particularly effective treatment options, while patients with lung cancer resistance not only delayed the treatment cycle but also caused strong side effects.